Anthera Pharmaceuticals, Inc. (ANTH) Shares Bought by Goldman Sachs Group Inc.
Goldman Sachs Group Inc. increased its stake in Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) by 1,376.1% during the first quarter, according to its most recent filing with the SEC. The firm owned 359,982 shares of the biopharmaceutical company’s stock after buying an additional 335,595 shares during the period. Goldman Sachs Group Inc. owned approximately 5.69% of Anthera Pharmaceuticals worth $153,000 as of its most recent SEC filing.
Separately, Sabby Management LLC boosted its position in Anthera Pharmaceuticals by 1,809.7% in the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 1,665,655 shares during the period. Institutional investors and hedge funds own 27.26% of the company’s stock.
Shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) traded up 6.6600% on Thursday, reaching $1.5999. 1,373,480 shares of the company’s stock were exchanged. Anthera Pharmaceuticals, Inc. has a one year low of $1.20 and a one year high of $27.36. The company has a 50 day moving average price of $1.41 and a 200 day moving average price of $1.19. The firm’s market cap is $17.45 million.
Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported $0.03 EPS for the quarter, topping the Zacks’ consensus estimate of ($1.09) by $1.12. Analysts expect that Anthera Pharmaceuticals, Inc. will post ($3.68) EPS for the current fiscal year.
Several research analysts recently weighed in on ANTH shares. Zacks Investment Research upgraded shares of Anthera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, June 13th. ValuEngine cut shares of Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, Jefferies Group LLC restated a “hold” rating and issued a $2.25 price objective on shares of Anthera Pharmaceuticals in a research report on Monday, May 15th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $10.11.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Stock Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.